|Day's Range||0.11 - 0.23|
|52 Week Range||0.02 - 6.49|
|PE Ratio (TTM)||-0.07|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The FDA approved the design of Delcath's clinical trial for its Melphalan HDS chemo delivery product.
DryShips, Merrimack Pharma, Gevo, Delcath Systems post new 52-week lows Friday.
Categories: Yahoo Finance Get free summary analysis Delcath Systems, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Delcath Systems, Inc. – AngioDynamics, Inc., Insulet Corporation, ICU Medical, Inc., Merit Medical Systems, Inc., Tandem Diabetes Care, Inc., Baxter International Inc. and Teleflex Incorporated (ANGO-US, PODD-US, ICUI-US, ... Read more (Read more...)